Projections indicate that Myopia could affect half the global population within a few decades. MyoLess offers a proactive approach to address this challenge in children.
Leveraging sophisticated free-form design, we’ve engineered our bifocal lens design with virtually invisible segment lines, delivering essential functionality while enhancing aesthetic appeal. The innovation reduces image jump while maintaining a sleek, modern appearance.
Using IOT advanced free-form technology, MyoLess lenses slow the progression of myopia through combatting ocular elongation. Clinical trials show an astonishing 39% lower increase in axial length growth in children after 12 months compared to single-vision lens wearers. We also recently published an updated study showing 29% lower increase in axial length growth after 24 months, demonstrating continued efficacy.
A lens design that ensures children with refractive errors have clear central vision while managing peripheral defocus
Children who experience extensive indoor and screen time, frequent close-up tasks, and genetic susceptibility are more at risk for Myopia. Practitioners recommend myopia management glasses for children 6+ years old with a refractive error of -0.50D to -1.00D.
Our myopia lens designs are compatible with standard single-vision blanks and any free-form manufacturing technology.
Talk to our team about how your lab can offer IOT MyoLess lenses.
*This product is not available in the US.*
Myo free-form technology in IOT’s myopic lenses ensures that all peripheral light focuses in front of the retina, unlike standard negative lenses which cause light to focus behind the peripheral retinal plane.
Incorporating progressive asymmetric peripheral defocus on the lens back surface results in a seamless power transition. This technology decelerates axial growth and myopia progression while providing sharp central vision surrounded by progressive power distribution.
Myopia management lenses are specifically
designed to slow the progression of myopia
in children, addressing a growing global concern.
Our MyoLess lens design offers numerous benefits
across our range of products for labs, eye care
professionals, and wearers.
| 1. | Proven efficacy in clinical trials makes prescribing one pair of glasses for every child easy. |
| 2. | Flexibility in manufacturing reduces laboratory costs and simplifies inventory management. |
| 3. | Increased patient satisfaction leads to increased loyalty and professional reputation. |
| 4. |
A versatile myopia solution allows labs broader portfolio offerings to accommodate a wide range of patient needs.
|
| 1. | Design technology slows myopia progression by reducing the rate of eye elongation. |
| 2. | Perfect vision in the central zone with minimal peripheral distortion. |
| 3. | A smooth surface and thinner lenses promise a natural appearance and enjoyable wear, combining comfort and aesthetics. |
MyoLess lenses are available in a wide range of materials and coatings, ensuring they meet each child's specific needs.
Our IOT Lens Design Software is compatible with almost any LMS, providing endless lens configuration options.
*This product is not available in the US*
MyoLess is based on a design of progressive and asymmetric peripheral defocus, featuring a central optical zone to ensure clear and comfortable vision. Surrounding this zone, the lens incorporates an asymmetric treatment area with positive power that creates controlled peripheral defocus, aimed at slowing myopia progression. Therefore, the rationale of the lens is based on known mechanisms to reduce myopia progression – peripheral positive/myopic defocus and asymmetric defocus.1-4
MyoLess is not a traditional progressive lens. A progressive design provides clear vision for the different distances, changing the power from the upper to the lower part of the lens. MyoLess has a central vision area free of blur with stable refraction in a small area around the geometric center. Around the optical area, MyoLess distributes positive power at the periphery in a wide area including the lateral (temporal and nasal) and lower parts of the lens.
It is well known that the retina is asymmetrical2-3. Especially, differences between nasal and temporal retina hemifields have been found for anatomical neural characteristics, peripheral refraction, and axial growth. MyoLess has been designed considering the morphological characteristics of the myopic retina having slightly higher positive power in the temporal area of the lens, inducing a higher defocus level in the nasal area of the retina.
MyoLess features a central optical zone approximately 7 mm wide horizontally, designed to provide clear and comfortable central vision. Surrounding this zone, the asymmetrical positive defocus is strategically calibrated at +1.8D on the temporal side, +1.5D on the nasal side, and +2.0D at the lower part of the lens. This configuration results from extensive internal clinical studies demonstrating that it offers the optimal balance between expected myopia management effectiveness, wearer adaptation, and overall usability.
The MyoLess clinical study has shown that the positive near power incorporated in the lower portion of MyoLess lenses does not negatively affect accommodation or binocular vision in children. After 12 months of use, binocular and accommodative functions of children using Myoless remained stable and were similar to those observed in children wearing single vision lenses. Additionally, the added positive power for near tasks improves lens usability and comfort during near activities such as reading and using digital devices.
MyoLess lenses have smooth power transitions that are invisible to the naked eye, maintaining a natural appearance similar to regular single vision lenses without visible lines or zones. Additionally, thanks to the positive power in the peripheral areas, the lens is considerably thinner than a standard single vision lens, resulting in a more aesthetically pleasing and lightweight lens.
The prescription range for MyoLess varies depending on the manufacturer but is generally comparable to that of
standard single vision lenses, as they are manufactured using free-form digital surfacing technology. This allows for broad customization across a wide range of prescriptions, including spherical powers, cylindrical corrections, and prisms.
MyoLess can be manufactured in any standard ophthalmic lens material, including polycarbonate, high-index, and CR-39. Likewise, they are compatible with all conventional lens treatments and coatings, such as anti-reflective coatings, scratch-resistant treatments, UV protection and tints.
MyoLess is a free-form lens, which makes it easier and less expensive to manufacture compared to other lenses. While many myopia management lenses require special semifinished lenses with treatment areas on the front surface, MyoLess creates the treatment area on the back surface using free-form technology. This allows the use of conventional spherical semi-finished lenses, reducing production complexity and cost.
A clinical trial conducted in Europe demonstrated that MyoLess lenses reduce axial length elongation by
approximately 39% after one year of use and about 29% after two years of follow-up. These results confirm
that MyoLess is an effective option for slowing myopia progression in children6-7.
The decrease in effectiveness over time is a common observation in myopia management treatments. The greatest impact typically occurs during the first year, while the relative percentage of reduction often appears smaller in subsequent years. This change may be influenced by adaptation processes or physiological changes in the eye over time8.
Recruitment of children for myopia control studies in Europe was challenging and took longer than expected due to the relatively low prevalence of progressive myopia in some regions. Consequently, the MyoLess study included 83 participants in the first year and 69 in the second year, which was a smaller sample size than desired. Despite this, the cohort was sufficient to demonstrate statistically significant outcomes, offering robust evidence of the lens’s efficacy.
The MyoLess study experienced a dropout rate of 17%, with participants decreasing from 83 in the first year to 69 in the second year. This was largely due to the study being initially planned for one year but later extended to two years, leading some patients to discontinue lens use after the first year. While this dropout rate presents a limitation, the remaining data still provide valuable insights into the lens effectiveness.
MyoLess lenses have demonstrated an axial length control
efficacy of 39% after one year and 29% after two years in a
randomized clinical trial conducted in Europe6-7. While some
other myopia control lenses on the market report efficacy
rates exceeding 50%9-10, these figures are primarily based on
studies conducted in Asian populations, where the rate and
pattern of myopia progression can differ significantly from
those observed in Europe. Therefore, direct comparisons
should be made with caution. Observational studies of other
lenses carried out in European populations report axial
elongation values similar to those seen with MyoLess11-13.
These findings suggest that the clinical performance of
MyoLess lenses in a European setting is comparable to that
of other leading myopia management lenses, demonstrating
robust efficacy even in populations with lower baseline
progression rates.
MyoLess lenses are typically recommended for children starting from around 6 years old, when they can reliably wear and care for spectacles. Early intervention at a young age is important for effective myopia management, but the decision should always be individualized based on the child’s visual needs and ability to adapt to the lenses.
Myopia management treatment is typically continued until myopia progression stabilizes, which often occurs in the mid to late teenage years. The decision to stop treatment should be based on regular eye exams showing minimal or no further progression of myopia. It’s important to monitor each patient individually, as the timing can vary depending on factors such as growth rate and visual demands.
In these cases, it is recommended to prescribe MyoLess lenses for both eyes as part of the myopia management treatment. Although only one eye is myopic, applying the MyoLess optical design to both eyes promotes binocular balance, reduces differences in visual quality, and improves adaptation to the treatment.
As with any myopia treatment, the best approach is to first correct myopia, then address binocular vision issues such as phorias or convergence insufficiency through vision therapy or prisms and finally control progression. The IOT lens, being free form, is the only one that allows the integration of prisms up to 4D.
Yes, MyoLess can be prescribed to a child who is currently using other myopia management spectacles or another myopia management strategy. It can be used as a substitute or as a complementary treatment, depending on the specific needs and clinical assessment of the patient.
The standard of care for myopia management according to the World Council of Optometry14 recommends measuring axial length and cycloplegic refraction. However, if cycloplegic refraction and biometry are not available, alternative evaluations can be done to check the progression of myopia. Mohindra retinoscopy performed in darkness or measurement of corneal curvature can provide an estimation of the growth of myopia.
Myopic children using myopia management spectacles should have follow-up evaluations every 6 months. This period allows the practitioner to monitor refractive error progression, axial length changes (if measured), visual acuity, and lens adaptation. However, the frequency may vary depending on individual risk factors such as fast myopia progression, young age at myopia onset, family history of high myopia, poor compliance of the treatment or suspected visual discomfort. In these cases, it is recommended more frequent monitoring (every 3–4 months).
When fitting MyoLess lenses initially, proper frame selection and an accurate lens centration are important to ensure comfort and glasses stability. The child’s binocular vision and accommodative status should be assessed beforehand. Expect a brief adaptation period during which the child may notice slight differences in peripheral vision. Clear communication with the patient and parents about lens benefits and adaptation expectations can improve compliance and comfort.
Similar to other lenses, the treatment zones of MyoLess lenses must fit properly within the frame to ensure effectiveness and comfort. A minimum distance of at least 10 mm from the pupil center to the top edge of the frame and 12 mm from the pupil center to the bottom edge is required. Studies show that once these minimum dimensions are met, the overall frame size does not affect the lens’s efficacy15.
To correctly dispense MyoLess lenses, you need to measure the monocular pupillary distance (PD) in the plane of the frame and the fitting height. These measurements ensure the lenses are accurately centered, positioning the treatment and correction zones correctly for optimal effectiveness and comfort.
MyoLess lenses have two engraved markings, similar to those found on progressive lenses, which are crucial for verifying correct lens alignment within the frame. To ensure proper positioning at collection, check that the frame is not twisted or bent, inspect the lenses for visible misalignment, have the patient try on the glasses for comfort, and confirm that the lens fitting cross aligns precisely with the patient’s pupil center.
When children begin wearing MyoLess lenses, a short adaptation period is normal. They may initially notice slight differences in peripheral vision or lens feel, but these sensations typically diminish within a few days to weeks. Proper fitting and clear instructions to both the child and parents help ensure a smooth transition and better compliance with the treatment.
Clinical evidence from various myopia management treatments shows that wearing the lenses for the full waking hours leads to better efficacy. Therefore, children are recommended to wear MyoLess lenses throughout the day during all their waking hours to maximize the myopia management benefits.
